tbuckley/cabot-search huggingface dataset:
FRI0154 The tolerability of vaccination against pneumococcus in children with juvenile idiopathic arthritis
Authors: M Soloshenko, E Alexeeva, T Bzarova, S Valieva, R Denisova, O Lomakina, K Isaeva, E Kashchenko, A Karaseva
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Children with chronic rheumatic diseases, including juvenile idiopathic artritis, are at high risk of bacterial and viral infections. The risk of complications and severity of infectious diseases are increased in immunosuppressive therapy due to given the long-term use. <h3>Objectives</h3> To evaluate the safety and tolerability of vaccination against pneumococcus in children with juvenile idiopathic arthritis. <h3>Methods</h3> The analysis included 39 patients with juvenile idiopathic arthritis who were in remission. Patients were divided into two groups, depending on the type of immunosuppressive therapy. Group 1 (n=24) consisted of patients receiving etanercept, mean age 5,4±2,5, observed 48 patient-years; Group 2 (n=15), patients who received methotrexate mean age 6,8±3,2, observed 30 patient-years. All patients had been vaccinated by 13-valent pneumococcal polysaccharide conjugate vaccine (13PPV). Recorded the incidence of infection diseases (such as pneumonia, tonsillitis, otitis media, etc.) in the 12 months prior to vaccination and 12 months after vaccination. All patients monitored the development of adverse events against the background of vaccination. <h3>Results</h3> The study showed a decrease in the incidence ofinfection diseases after vaccination in the first group from 5,4±1,66 to 1,7±0,77, in second group from 4,4±1,05 to 1,6±0 73, (p&lt;0.05). Adverse events related to vaccination are presented in the table. Results of the study showed no relapse of the underlying disease following immunization. Adverse events related to vaccination are presented in the table. <h3>Conclusions</h3> The results showed a good tolerability of the vaccine, no relapse of the underlying disease following immunization, as well as a statistically significant (p&lt;0.05) reduction in the incidence following immunization. <h3>Disclosure of Interest</h3> M. Soloshenko: None declared, E. Alexeeva Grant/research support from: Roche, Abbott, Pfizer, Bristol-Myers Squibb, Centocor, Novartis., Speakers bureau: Roche, Merck Sharp &amp; Dohme, Abbott, Bristol-Myers Squibb, Medac, Novartis, Pfizer, T. Bzarova Grant/research support from: Roche, Pfizer, Speakers bureau: Roche, Merck Sharp &amp; Dohme, Abbott, Pfizer, S. Valieva Grant/research support from: Roche, Bristol-Myers Squibb, Speakers bureau: Roche, Merck Sharp &amp; Dohme, Bristol-Myers Squibb, Medac, Novartis, R. Denisova Grant/research support from: Roche, Centocor, Novartis, Speakers bureau: Roche, Merck Sharp &amp; Dohme, Abbott, Medac, O. Lomakina: None declared, K. Isaeva: None declared, E. Kashchenko Grant/research support from: Novartis, A. Karaseva: None declared
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Authors: Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong, Marcus W. Bosenberg
Journal: Journal for ImmunoTherapy of Cancer (2017)

Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, "Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy" as part of the SITC 31st Annual Meeting and Associated Programs on November 10, 2016 in National Harbor, MD. The workshop focused on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in cancer modeling that are anticipated in the near future. This full-day program provided an introduction to the most common immunocompetent and humanized models used in cancer immunology and immunotherapy research, and addressed the use of models to evaluate immune-targeting therapies. Here, we summarize the workshop presentations and subsequent panel discussion.
Are MRI-detected erosions specific for RA? A large explorative cross-sectional study
Authors: Debbie M Boeters, Wouter P Nieuwenhuis, Hanna W van Steenbergen, Monique Reijnierse, Robert B M Landewé, Annette H M van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> MRI is recommended in the diagnostic process of rheumatoid arthritis (RA) to detect joint damage early. MRI-detected erosions are also present in symptom-free controls, especially at older age. It is unclear if RA-specific MRI-detected erosions can be distinguished from 'physiological' erosions in symptom-free individuals. This study compared MRI-detected erosions of patients with RA with healthy controls and with other arthritides. <h3>Methods</h3> 589 newly presenting patients with early arthritis (238 RA, 351 other arthritides) and 193 symptom-free controls underwent contrast-enhanced 1.5T MRI of unilateral metacarpophalangeal and metatarsophalangeal (MTP) joints. Total erosion score (according to the Rheumatoid Arthritis MRI Scoring System), number, severity, location of erosions and simultaneous presence of MRI-detected inflammation (synovitis and/or bone marrow oedema) were compared; participants were categorised in three age groups (&lt;40, 40–59, ≥60). <h3>Results</h3> Patients with RA had statistically significant higher total erosion scores than controls but scores of individual persons largely overlapped. Grade ≥2 erosions and MTP5 erosions were specific for RA (specificity 98%–100% and 90%–98% for different age groups). MTP1 erosions were only specific if aged &lt;40 (specificity 98%) and erosions with inflammation if aged &lt;60 (specificity 91%–100%). ≥1 of the mentioned erosion characteristics were present in 29% of patients with RA. Comparing patients with RA with other arthritides revealed that grade ≥2 erosions and MTP5 erosions remained specific for RA (specificity ≥89%) as well as MTP1 erosions if aged &lt;40 (specificity 93%), in contrast to erosions combined with inflammation (specificity 49%–85%). <h3>Conclusions</h3> Total erosion scores of individual persons were largely overlapping. Erosion characteristics specific for RA were identified, but were infrequently present. Caution is needed not to overestimate the value of MRI erosions in the diagnostic process.
SAT0623 Correlations between clinical, ultrasound and disease activity scores of peripheral enthesitis in spondyloarthritis (SPA)
Authors: A Haddouche, S Haid, S Bencheikh, S Slimani, A Abdessemed, N Brahimi, A Ladjouze
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To look for correlations between clinical, ultrasound (US) and disease activity scores of peripheral enthesitis in an SpA cohort. <h3>Methods</h3> A prospective study of all SpAs meeting SpA ASAS criteria followed at EHS Ben Aknoun, over a period from January 2015 to April 2016. Seventeen entheseal sites were assessed bilaterally: insertions of supra-spinatus, infra-spinatus, sub-scapular, medial and lateral epicondylars, triceps brachialis, gluteus midius and minimus, quadricipital, proximal and distal insertion (patellar ligament, medial and lateral collateral ligament), Achilles tendon and plantar aponeurosis. Peripheral entheses was assessed by the following clinical scores: Enthesitis Peripheral Score (PES= Sum of symptomatic peripheral entheses sites on clinical examination), Visual Analog Scale of peripheral enthesitis (VAS), Spondyloarthritis Research Consortium of Canada score (SPARCC) as well as the following US enthesitis scores: Acute Enthesitis score (Sum of acute enthesitis US scores for each site), Chronic Enthesitis score (Sum of US chronic enthesitis scores for each site), Global Enthesitis score (Sum of the acute and chronic US scores of enthesitis), Doppler signal Enthesitis score (Sum of Doppler signal scores less than 2mm from cortical bone for each site), Madrid Sonography Enthesitis Index (MASEI), Simplified Echographic Score (SES) wich assesses only the Achilles tendon and the plantar aponeurosis. Correlations between clinical, activity and US scores were investigated by SPPSS software. <h3>Results</h3> A total of 208 patients were included. At examination 88.9% had an active disease and 64.4% of SpA were taking NSAIDs. 6240 entheses were assessed clinically and with US. A positive correlation was found between activity scores and two clinical scores (Peripheral Enthesitis Score, SPARCC). A good correlation was found between Activity scores and all US scores on one hand and with SPARCC scores and PES scores on the other hand. For US and clinical correlations, only Doppler scores was positively correlated with 2 clinical scores (SPARCC and PES scores), Acute Enthesitis scores was correlated with the PES scores. No correlation was found between clinical scores and MASEI or SES scores. No correlation was found with the mean enthesitis VAS scores. <h3>Conclusions</h3> All US enthesitis scores were correlated with disease activity scores but those correlated with the clinical symptoms and not with its intensity were: Acute Enthesitis Scores, Global Enthesitis Scores and especially Doppler signal Enthesitis Scores. <h3>Disclosure of Interest</h3> None declared
Task Shifting in Dermatology
Authors: Danielle N. Brown, Sinéad M. Langan, Esther E. Freeman
Journal: JAMA Dermatology (2017)

Can task shifting be used to improve the delivery of dermatologic care in resource-poor settings worldwide?Task shifting is a means of redistributing available resources, whereby highly trained individuals train an available workforce to provide necessary care in low-resource settings. Limited evidence exists for task shifting in dermatology; however, studies from psychiatry demonstrate its efficacy. In the field of dermatology there is a need for high-quality evidence including randomized clinical trials to validate the implementation of task shifting in low-resource settings globally.
FRI0131 The 2010 acr/eular criteria are insufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: results from the leiden-eac and espoir cohorts
Authors: D Boeters, C Gaujoux-Viala, A Constantin, A van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The 2010-ACR/EULAR criteria were derived to classify RA earlier in time. Previous studies indeed observed that the 2010-criteria were fulfilled earlier than the 1987-criteria. This study determined whether the 2010-criteria perform equally in the early detection of autoantibody-positive and autoantibody-negative RA. <h3>Objectives</h3> To compare the performance of the 2010-criteria between autoantibody-positive and autoantibody-negative RA within two different early arthritis cohorts. <h3>Methods</h3> From the total Leiden-EAC (n=3448) and ESPOIR (n=813) RA-patients who fulfilled the 1987-RA criteria at 1-year but not at presentation were selected (n=515 and n=53, respectively). These RA-patients were studied on the presence of ACPA and RF, and on fulfilling the 2010-criteria at baseline, as 2010-positivity indicated that these RA-patients were earlier identified. <h3>Results</h3> In the EAC, 67% of the selected RA-patients did already fulfil the 2010-criteria at baseline. In ESPOIR this was 57%, indeed demonstrating early classification with the 2010-criteria. Among the selected autoantibody-positive RA-patients of the EAC, 85% was identified at baseline already with the 2010-criteria. Within autoantibody-negative RA this was 45% (p&lt;0.001). Similarly within autoantibody-positive RA-patients in ESPOIR 92% was 2010-positive at baseline, whereas this was only 25% within autoantibody-negative RA (p&lt;0.001). <h3>Conclusions</h3> The 2010-criteria perform well in the early identification of autoantibody-positive RA, but autoantibody-negative RA-patients are still frequently missed with these criteria. As it has been demonstrated that early treatment initiation is beneficial for the outcome of ACPA-negative RA as well, other diagnostics are required for the early identification of ACPA-negative RA. <h3>Disclosure of Interest</h3> None declared
THU0435 Pharmacodynamics, pharmacokinetics, and safety of verinurad (RDEA3170) in combination with febuxostat versus febuxostat alone and verinurad alone in japanese adults with gout or asymptomatic hyperuricemia: a phase 2A, open-label study
Authors: M Shiramoto, S Liu, Z Shen, J Hall
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. <h3>Objectives</h3> This Phase 2a, randomized, open-label, single-site study investigated the multiple-dose pharmacodynamics (PD), pharmacokinetics (PK), and safety of oral verinurad in combination with febuxostat versus febuxostat alone and verinurad alone in Japanese male adults with gout or asymptomatic hyperuricemia (NCT02317861). <h3>Methods</h3> Japanese male patients aged ≥20 and ≤70 years with gout or asymptomatic hyperuricemia and serum uric acid (sUA) ≥8 mg/dL were randomized to 1 of 6 cohorts to receive febuxostat (10 mg, 20 mg, and 40 mg) alone, febuxostat in combination with verinurad (dose range 2.5 mg to 10 mg); verinurad (2.5 mg to 15 mg) alone; or benzbromarone (50 mg) alone (4 treatment periods per cohort, each treatment period 7 days). The study drugs were administered once daily in the morning after breakfast. Serial blood and urine samples were measured at preset intervals on Days -1, 1, 2, 7, 8, 14, 15, 21, 22, 28 and 29 for PD and PK endpoints. Safety assessments included adverse events (AEs) and laboratory, electrocardiograms, and vital sign parameters. <h3>Results</h3> Seventy-two patients with gout (n=37) or hyperuricemia (n=35) were randomized in this study. Addition of verinurad (2.5 mg to 10 mg) to febuxostat (10 mg, 20 mg, or 40 mg) decreased sUA in dose-dependent manner (Figure). Verinurad coadministered with febuxostat increased the amount of uric acid recovered in urine (Aeur), compared with baseline and the same dose of febuxostat administered alone, yet comparable with benzbromarone. Plasma Cmax and AUC exposures of verinurad and febuxostat exhibited dose proportional increases within the investigated dose range. No clear PK drug-drug interaction of verinurad and febuxostat with each other was observed. Verinurad at doses from 2.5 mg to 15 mg was well tolerated, with no serious AEs or withdrawals due to AEs. One treatment-emergent AE (diarrhea) was considered possibly related to both verinurad and febuxostat. Laboratory values and vital signs indicated no clinically meaningful changes. <h3>Conclusions</h3> Verinurad coadministered with febuxostat dose-dependently decreased sUA while maintaining Aeur comparable to benzbromarone. All dose combinations of verinurad and febuxostat in this study were generally well tolerated. <h3>Disclosure of Interest</h3> M. Shiramoto Employee of: SOUSEIKAI PS Clinic, S. Liu Employee of: Ardea Biosciences, Inc., Z. Shen Employee of: Ardea Biosciences, Inc., J. Hall Employee of: Ardea Biosciences, Inc.
Shortage or Surplus of Physicians in the United States
Authors: Amy W. Farnbach Pearson, Richard S. Larson
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annals Story Slam - Luther
Authors: Samir C. Grover
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 September 2017Annals Story Slam - LutherFREESamir C. Grover, MDSamir C. Grover, MDFrom University of Toronto, Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0059 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Luther "Luther," by Dr. Samir C. Grover (Duration 04:48)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Toronto, Toronto, Ontario, Canada.Current Author Address: Samir C. Grover, MD, University of Toronto, Toronto, Ontario, Canada; e-mail, samir.[email protected]utoronto.ca. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: SS1 ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
A wound-healing program is hijacked to promote cancer metastasis
Authors: Leif W. Ellisen
Journal: The Journal of Experimental Medicine (2017)

In this issue of JEM, Sundaram et al. (https://doi.org/10.1084/jem.20170354) report a mechanism by which the normal epithelial wound healing response is “hijacked” to promote invasion and metastasis in head and neck squamous carcinomas (HNSCCs), a finding that unveils new markers of poor outcomes and potential targets for therapeutic intervention.
AB1230-HPR A survey to establish current practice in addressing work issues among people with inflammatory arthritis in the irish clinical setting
Authors: Y Codd, T Stapleton, R Mullan, D Kane
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Inflammatory arthritis strongly correlates with work disability. Treatment guidelines recommend work support but data are lacking on rheumatology clinicians9 perspectives on work referral and extent of work support within current rheumatology services for this population. <h3>Objectives</h3> To scope the need for and patterns of work referral, and examine the extent and type of work support currently available in Irish rheumatology services for people with inflammatory arthritis. To identify factors that help or hinder employment-related service provision. To explore the role of occupational therapy in addressing work with this population from the perspectives of the other members of the rheumatology team and current practices and challenges. <h3>Methods</h3> A questionnaire concerning work support provision was distributed via online survey to doctors, nurses and physiotherapists working in clinical rheumatology in Ireland. <h3>Results</h3> Response rate of 22% was achieved and total sample of 73 analysed. Respondents indicated that 71% of service users were of working age and the majority of respondents (95%) agreed that addressing employment retention was within the remit of rheumatology services. Over half of respondent (55%) of respondents estimated that 25–49% of their caseload had work needs. Work was usually addressed if clients raised work concerns (94%), client reports work absenteeism (83%), client9s work involved manual component (75%). Barriers to addressing work included limited time in clinical setting (92%); unfamiliarity with best practice for work support (91%); lack of perceived competency to assess work complexities (82%). Occupational therapy (OT) was identified as the most appropriate profession to address work (78%). However, 51% respondents reported not routinely referring to OT for work support due to limited availability of OT (13% of responders having no access to OT); uncertainty regarding optimum timing for work intervention, and uncertainty as to what OT could offer regarding work. <h3>Conclusions</h3> Addressing work was recognised as multifaceted and multidisciplinary. Work needs are addressed within current rheumatology services only when the client themselves initiate the issue. Opportunity exists to improve the quality of services to address work in line with guidelines by educating the multidisciplinary team about available work services and implementation of a clinical pathway for employment retention. <h3>Disclosure of Interest</h3> None declared
AB0491 The association of baseline hyperuricemia in premenopausal women with systemic lupus erythematosus and development of nephritis
Authors: DH Lim, S Hong, JS Oh, Y-G Kim, C-K Lee, SW Choi, B Yoo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Renal involvement is a common and serious manifestation of SLE. Hyperuricemia may be associated with lupus nephritis as a result of renal damage. However, it is not yet well known whether hyperuricemia is independently associated with renal involvement even in patients without known predisposing factors for hyperuricemia such as decreased renal function, old age, male gender, menopause, and drugs. <h3>Objectives</h3> The aim of this study was to evaluate the association of baseline serum uric acid level and development of nephritis in patients diagnosed with SLE. <h3>Methods</h3> We retrospectively reviewed electronic medical records of 101 female SLE patients whose ages at the time of diagnosis (baseline) were 45 years old or below in a tertiary medical center from January 2000 to March 2015. SLE with renal involvement was diagnosed when patients met the renal disorder of the 1997 ACR criteria for SLE. We compared baseline serum uric acid levels of the SLE patients who had nephritis at the time of diagnosis or later (nephritis group) with the patients who had not developed nephritis (non-nephritis group) during follow-up period. <h3>Results</h3> Among 101 patients, 22 (22%) had hyperuricemia (serum uric acid ≥6 mg/dL) at baseline and 45 (45%) had developed nephritis during follow-up period (median 6.1 years). There were significant differences in baseline serum uric acid level, glomerular filtration rate (GFR), anti-dsDNA antibody and complement level between non-nephritis group and nephritis group (Table). Interestingly, among 59 patients with normal renal function (baseline GFR ≥90 mL/min/1.73m<sup>2</sup>), baseline serum uric acid level was also significantly higher in the nephritis group than non-nephritis group (Table). Moreover, the patients with hyperuricemia at baseline were more likely to develop nephritis than those without hyperuricemia during follow-up period (64% vs. 39%, <i>p</i> =0.042) (Figure). <h3>Conclusions</h3> These findings suggest that high serum uric acid level at the time of diagnosis in premenopausal women with SLE may be independently associated with nephritis. More careful evaluation would be required for development of nephritis in such patients. <h3>Disclosure of Interest</h3> None declared